| CEO: | Jeremy Skillington |
| CFO: | Ian O’Connel |
| Executive Chairman: | Cathal Friel |
| Independent Non-Executive Director: | Luke O’Neill |
| Independent Non-Executive Director: | Brendan Buckley |
| Independent Non-Executive Director: | Edward Gibson |
| Non-Executive Dir: |
| Address: | 40 Bank Street, Floor 24, London, United Kingdom, E14 5NR |
| Phone: | +44 (0)20 7183 1499 |
| Website: | http://www.poolbegpharma.com/ |
| Sector: | Pharma and Biotech(LSE) |
| Index: | FTSE AIM All-Share |
| ISIN: | GB00BKPG7Z60 |
| Currency | UK Pounds |
| Share Price | 4.00p |
| Closing Price Change | 0.000p |
| % Change | 0.00 % |
| 52 Week High | 0.000p |
| 52 Week Low | 0.000p |
| Volume | 0 |
| Shares Issued | 697.20m |
| Value |
|
|---|
| Price Trend |
|
|---|
| Income | ![]() |
|---|
| Growth | ![]() |
|---|
| No dividends found |
| Time | Volume / Share Price |
| 12:34 | 134,812 @ 3.70p |
| 11:59 | 16,524 @ 3.80p |
| 11:57 | 7,900 @ 3.80p |
| 11:53 | 1,000 @ 3.70p |
| 10:54 | 70,000 @ 3.70p |
| CEO | Jeremy Skillington |
| CFO | Ian O’Connel |
You are here: research